ASH 2021 | ZUMA-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk LBCL
Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the design and results of ZUMA-12, a Phase II clinical trial evaluating axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients with high-risk large B-cell lymphoma (LBCL) (NCT03761056). The complete response (CR) rate was 78% and the best overall response rate (ORR) was 78%. After a median follow-up of 16 months, 73% of patients remained in remission. In addition, there were no new safety signals observed with axi-cel treatment compared to previous studies. Interestingly, chimeric antigen receptor T-cell (CAR-T) expansion was greater in the first-line setting than in previous clinical trials evaluating axi-cel in patients who had received three or more prior lines of therapy. This data suggests that axi-cel is an effective strategy in the first-line setting, but further studies evaluating this CAR-T therapy and comparing it to chemoimmunotherapy are required. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
